Worcester, USA - 25 Sep `19Dermavant Sciences: Cerdulatinib Gel

Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo. 

In Brief: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks

Ages Eligible:  18 Years to 70 Years

Start Date: September 25, 2019

Completion Date (estimated): July 2020

Status: Active, recruiting

Study ID

  • ClinicalTrials.gov: NCT04103060
  • Other Study ID Numbers: DMVT-502-2101

Location: Dermavant Investigational Site: Worcester, Massachusetts, United States, 01605

Contact: To learn more about this study, you or your doctor may contact Dermavant Sciences by phone +1-480-666-0844 or email dermavantclinicaltrials@dermavant.com. Please refer to this study by its ClinicalTrials.gov identifier (NCT number)

FAQOther Questions

  • How can I cure vitiligo?

    There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...

  • Which skin conditions can be mistaken for vitiligo?

    Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...

  • Can chemicals cause vitiligo?

    It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...